Meeting
2017 ASCO Annual Meeting
VXM01 phase I study in patients with resectable progression of a glioblastoma.
Authors
Wolfgang Wick
Neurology Clinic, DKFZ, DKTK, Heidelberg, Germany
Wolfgang Wick , Antje Wick , Martha Nowosielski , Felix Sahm , Dennis Riehl , Marlene Arzt , Andreas von Deimling , Martin Bendszus , Philipp Kickingereder , David Bonekamp , Philipp Beckhove , Friedrich Hubertus Schmitz-Winnenthal , Christine Jungk , Sébastien Wieckowski , Christel Herold-Mende , Heinz Lubenau , Andreas Unterberg , Michael Platten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02718443
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2061)
DOI
10.1200/JCO.2017.35.15_suppl.2061
Abstract #
2061
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
VXM01 phase I study in patients with progressive glioblastoma: Final results.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2020 ASCO Virtual Scientific Program
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
First Author: Patrick Y. Wen
Poster
2019 ASCO Annual Meeting
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
First Author: Andrew B. Lassman